Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Pneumococcal Immunization, Healthy Volunteers
Interventions: PCV21 vaccine, 20vPCV licensed vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: NurOwn® (MSC-NTF cells), Placebo, Bone Marrow aspiration; Biological · Other
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Lower Limb Amputation Above Knee (Injury), Congenital Amputation of Lower Limb, Lower Limb Amputation Knee
Interventions: Kenevo or C-Leg 4, Non microprocessor controlled knee (NMPK); Device
Lead sponsor: Otto Bock Healthcare Products GmbH; Industry
Eligibility: 65 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 85 more

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Conditions: Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Interventions: GNSC-001, transient immune-modulation, Placebo; Genetic · Drug
Lead sponsor: Genascence Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Mobile, Alabama • La Mesa, California • San Diego, California + 6 more

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Diabetes, Hypoglycemia
Interventions: BHT-3021, BHT-Placebo; Drug
Lead sponsor: Bayhill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Aurora, Colorado + 7 more

Conditions: Major Depressive Disorder (MDD)
Interventions: PRX-00023, Placebo for PRX-00023; Drug
Lead sponsor: Epix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 21
States / cities: Mesa, Arizona • Encino, California • Los Alamitos, California + 18 more

Conditions: Achondroplasia
Interventions: Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Neonatal Abstinence Syndrome
Interventions: Methadone, Diluted Deodorized Tincture of Opium; Drug
Lead sponsor: Eastern Maine Medical Center; Other
Eligibility: 1 Day to 6 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bangor, Maine

Conditions: Bipolar Disorder, Mania
Interventions: Lithium Carbonate Capsule; Drug
Lead sponsor: JDS Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin Collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Anniston, Alabama • Las Vegas, Nevada

Conditions: Inferior Alveolar Nerve, Mandibular Nerve Blocks
Interventions: 2% Lidocaine with 1:100,000 epinephrine; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 70 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pain
Interventions: 30 Minute Comedy Video, 30 Minute Documentary Video; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 20 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Otitis Media, Otitis Media Chronic, Otitis Media Effusion, Otitis Media Recurrent, Otitis Media in Children
Interventions: CLiKX® Tympanostomy Tube Delivery System; Device
Lead sponsor: ClinQure, Inc.; Network
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Louisville, Kentucky • Houston, Texas • Mesquite, Texas + 1 more

Conditions: Flank Mass
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: Femoral Nerve Catheters, Single Shot Femoral Nerve Blocks; Drug
Lead sponsor: Eastern Maine Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Bangor, Maine

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more

Conditions: Cerebral Palsy, Motor Deficits
Interventions: Pediatric Constraint-Induced Movement therapy, Conventional pediatric motor rehabilitation therapy; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 6 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bipolar Disorder
Interventions: Placebo, lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 19
States / cities: Burbank, California • Loma Linda, California • San Diego, California + 16 more

Conditions: Acute Ischemic Stroke
Interventions: NeuroThera® Laser System; Device
Lead sponsor: PhotoThera, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encinitas, California + 23 more

Conditions: Major Depressive Disorder
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more

Conditions: Pulmonary Fibrosis, Anxiety
Interventions: Digital cognitive behavioral therapy; Device
Lead sponsor: Vicore Pharma AB; Industry
Eligibility: 22 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: San Francisco, California • Salt Lake City, Utah

Conditions: Critical Illness
Interventions: WFIT; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients

Assessing Outcomes With Microprocessor Knee Utilization in a K2 Population

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Treatment of Neonatal Abstinence Syndrome

Safety and Efficacy Study of Lithium in Bipolar Disorder

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

Use of CBCT to Improve Inferior Alveolar Nerve Block Success

Mirthful Laughter and Muscle Soreness / Pain

CLIKX® Tympanostomy Tube Delivery System for the Placement of Tympanostomy Tubes

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy

Depression And Bipolar Disorder

Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF

Wake Forest Post-ICU Telehealth (WFIT) Program